terizidone has been researched along with bedaquiline in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andries, K; Bantubani, N; De Marez, T; Diacon, AH; Donald, PR; Grobusch, M; Lounis, N; Mahanyele, R; McNeeley, DF; Meyvisch, P; Narasimooloo, R; Patientia, RF; Pym, A; van Heeswijk, R | 1 |
| Boulle, A; Fox, T; Khomo, N; Kock, Y; Leslie, J; Manning, K; Meintjes, G; Mudaly, V; Stewart, A; Tiffin, N; Wasserman, S; Zhao, Y | 1 |
| Martins Dos Santos, VAP; Rienksma, RA; Schaap, PJ; Suarez-Diez, M | 1 |
1 trial(s) available for terizidone and bedaquiline
| Article | Year |
|---|---|
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.
Topics: Antitubercular Agents; Clarithromycin; Cycloserine; Dapsone; Diarylquinolines; Erythromycin; Female; Humans; Isoxazoles; Male; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis, Multidrug-Resistant | 2012 |
2 other study(ies) available for terizidone and bedaquiline
| Article | Year |
|---|---|
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Female; HIV; HIV Infections; Humans; Isoniazid; Isoxazoles; Levofloxacin; Male; Mycobacterium tuberculosis; Oxazolidinones; Pyrazinamide; Retrospective Studies; South Africa; Survival Analysis; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
Modeling Host-Pathogen Interaction to Elucidate the Metabolic Drug Response of Intracellular
Topics: Adenosine Triphosphatases; Amides; Amino Acids; Antitubercular Agents; Cycloserine; Diarylquinolines; Drug Tolerance; Ethambutol; Ethionamide; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Host-Pathogen Interactions; Humans; Isoniazid; Isoxazoles; Metabolic Networks and Pathways; Models, Biological; Mycobacterium bovis; Mycobacterium tuberculosis; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis | 2019 |